Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novelion Therapeutics
Company Location: VANCOUVER A1 V6B 0M3
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Retinitis Pigmentosa|Leber Congenital Amaurosis
Phase 2: Other
Phase 1: Retinitis Pigmentosa|Leber Congenital Amaurosis|Blindness|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2013-005393-22 | P3 |
Terminated |
Leber Congenital Amaurosis|Retinitis Pigmentosa |
2020-10-03 |
|
| RPE65 | P1 |
Completed |
Retinitis Pigmentosa |
2014-07-01 |
|
| RET IDA 02 | P2 |
Completed |
Other |
2014-06-01 |
|
| 2011-004214-42 | P1 |
Completed |
Leber Congenital Amaurosis|Retinitis Pigmentosa |
2014-05-16 |